<html>
<head>PUBMED IDs for KIAA0247</head>
<body bgcolor='#C5F0F2'><h1>KIAA0247</h1><a href='https://pubmed.ncbi.nlm.nih.gov/16288013/'>The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress.</a> November 17  2005<br><a href='https://pubmed.ncbi.nlm.nih.gov/20236627/'>Characterization of SVEP1, KIAA, and SRPX2 in an in vitro cell culture model of endotoxemia.</a> August 26  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/21619678/'>A predicted protein, KIAA0247, is a cell cycle modulator in colorectal cancer cells under 5-FU treatment.</a> September 13  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/24357125/'>Deletions in 14q24.1q24.3 are associated with congenital heart defects, brachydactyly, and mild intellectual disability.</a> November 5  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/24652652/'>DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that cooperates with p53 as oncosuppressor. [Corrected].</a> June 3  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/27893430/'>KIAA0247 suppresses the proliferation, angiogenesis and promote apoptosis of human glioma through inactivation of the AKT and Stat3 signaling pathway.</a> November 29  2016<br></body></html>
